Journal
MOLECULAR IMMUNOLOGY
Volume 150, Issue -, Pages 47-57Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.molimm.2022.08.005
Keywords
Isocitrate lyase; Inhibitor; Enzymatic Assay; scFv; Phage Display; Monoclonal Antibodies
Categories
Funding
- Malaysian Ministry for Higher Ed- ucation through the Fundamental Research Grant Scheme [FRGS/1/2018/STG05/USM/02/2]
Ask authors/readers for more resources
This study focuses on the use of monoclonal antibodies as an alternative antibacterial treatment. It identifies a specific antibody that can inhibit the growth mechanisms of Mycobacterium tuberculosis, potentially providing a solution to antibiotic resistance.
The increasing incidence reports of antibiotic resistance highlights the need for alternative approaches to deal with bacterial infections. This brought about the idea of utilizing monoclonal antibodies as an alternative antibacterial treatment. Majority of the studies are focused on developing antibodies to bacterial surface anti-gens, with little emphasis on antibodies that inhibit the growth mechanisms of a bacteria host. Isocitrate lyase (ICL) is an important enzyme for the growth and survival of Mycobacterium tuberculosis (MTB) during latent infection as a result of its involvement in the mycobacterial glyoxylate and methylisocitrate cycles. It is postu-lated that the inhibition of ICL can disrupt the life cycle of MTB. To this extent, we utilized antibody phage display to identify a single chain fragment variable (scFv) antibody against the recombinant ICL protein from MTB. The soluble a-ICL-C6 scFv clone exhibited good binding characteristics with high specificity against ICL. More importantly, the clone exhibited in vitro inhibitory effect with an enzymatic assay resulting in a decrease of ICL enzymatic activity. In silico analysis showed that the scFv-ICL interactions are driven by 23 hydrogen bonds and 13 salt bridges that might disrupt the formation of ICL subunits for the tertiary structure or the formation of active site beta domain. However, further validation is necessary to confirm if the isolated clone is indeed a good inhibitor against ICL for application against MTB.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available